Skip to main content
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. — Investor Relations & Filings

Ticker · OKUR ISIN · US75974E1038 US Manufacturing
Open in API
Filings indexed 342 across all filing types
Latest filing 2021-04-08 Regulatory Filings
Country US United States of America
Listing US OKUR

About OnKure Therapeutics, Inc.

https://onkuretherapeutics.com/

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer patients. The company is building a pipeline of potentially best-in-class, tumor-agnostic therapies that target biologically validated drivers of cancers, particularly those underserved by current treatments. Its research and development efforts are centered on novel and potentially less toxic kinase inhibitor drugs and epigenetic therapies.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-04-08 English
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC for registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It describes the registration of common stock on The Nasdaq Stock Market LLC. The document is a regulatory filing related to securities registration, not a financial report, earnings release, or other specific report types. It is short (3285 characters) and contains no financial statements or detailed analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other categories.
2021-04-06 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding a Registration Statement on Form S-1 for Reneo Pharmaceuticals, Inc. It is an acceleration request for the effective time of the Registration Statement under Rule 461 of the Securities Act of 1933. The letter is signed by representatives of the underwriters. This type of document is related to capital raising activities and the registration of securities for public offering. It is not a financial report, earnings release, or management discussion. It is an update on the capital raising process, specifically the acceleration of the effective date of a registration statement. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and it is not announcing a report publication, so it is not RPA. Confidence is high given the clear context and regulatory references.
2021-04-06 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from Reneo Pharmaceuticals, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references the Registration Statement and the Securities Act of 1933, but does not contain financial data or the Registration Statement itself. The document is short (2084 characters) and is a formal request related to a filing, not the filing itself. Therefore, it is an announcement or correspondence related to a regulatory filing, not the filing itself. According to the rules, such documents are classified as Regulatory Filings (RNS).
2021-04-06 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC by Reneo Pharmaceuticals, Inc. The Form S-1 is a registration statement used for initial public offerings (IPOs) and other securities offerings under the Securities Act of 1933. The text includes details about the offering, the company, risk factors, use of proceeds, management, and other typical prospectus information. It is not a financial report, earnings release, or management discussion but a regulatory filing related to capital raising and securities registration. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual filing, not just an announcement or certification.
2021-04-05 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm responding to comments from the SEC staff regarding a draft Registration Statement on Form S-1 for Reneo Pharmaceuticals, Inc. It discusses revisions made to the Registration Statement in response to SEC comments, including disclosures about clinical trial results, use of proceeds, dilution tables, intellectual property, and other regulatory compliance matters. The document is not the Registration Statement itself but a correspondence addressing SEC comments on the draft filing. It is a regulatory correspondence related to a securities offering registration process, not a financial report, earnings release, or other specific report type. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other categories.
2021-03-19 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.